Appili Therapeutics Inc.
APLI.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2,120.59% | -- | -201.15% | -77.99% | -98.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,120.59% | -- | -201.15% | -77.99% | -98.65% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2,120.59% | -- | -201.15% | -77.99% | -98.65% |
| SG&A Expenses | -13.69% | -16.88% | 11.40% | -30.05% | -19.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.71% | -43.06% | -2.47% | -12.00% | 46.32% |
| Operating Income | 52.43% | 43.06% | 1.50% | -4.44% | -79.29% |
| Income Before Tax | -27.26% | 23.95% | 121.95% | -255.07% | 21.87% |
| Income Tax Expenses | 2,722.22% | -- | 192.42% | -257.78% | -97.12% |
| Earnings from Continuing Operations | -31.74% | 22.02% | 119.41% | -234.46% | 25.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.74% | 22.02% | 119.41% | -234.46% | 25.13% |
| EBIT | 52.43% | 43.06% | 1.50% | -4.44% | -79.29% |
| EBITDA | 52.50% | 43.12% | 1.49% | -4.42% | -79.53% |
| EPS Basic | -31.11% | 22.92% | 119.40% | -244.44% | 25.00% |
| Normalized Basic EPS | -28.57% | 25.00% | 121.43% | -233.33% | 22.22% |
| EPS Diluted | -31.11% | 22.92% | 119.40% | -244.44% | 25.00% |
| Normalized Diluted EPS | -28.57% | 25.00% | 121.43% | -233.33% | 22.22% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |